ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Unexplained long-term increase in intraocular pressure during the treatment of macular disease with intravitreal anti-VEGF.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate the incidence and timing of unexplained intraocular pressure (IOP) increase over time following the administration of various intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for macular diseases. PATIENTS AND
methodsThis retrospective study included 2611 eyes treated multiple times with one or more different anti-VEGF agents between 2016 and 2022. An IOP increase of ≥ 25 mmHg was classified as pathological. We analyzed the incidence rates, the timing of the IOP increase during the administered therapy and the thickness of the retinal nerve fiber and ganglion cell layer over two years in eyes with IOP increase.
resultsA total of 50 eyes (1.9%) from 48 patients experienced an increase in IOP during anti-VEGF therapy. In 15 eyes, the increase was attributable to other ocular diseases (such as neovascular glaucoma, uveitis, or endophthalmitis), and these eyes were therefore excluded from further analysis. In contrast, 35 eyes (1.3%) from 33 patients with an average age of 68.4 ± 10,0 years, developed an unexplained increase in IOP up to an average of 27 [25-45] mmHg, typically after 12 [1-35] weeks. 97% of the affected eyes had no history of glaucoma. The baseline IOP was 16 [12-20] mmHg. In 24 eyes (68%), short-term topical therapy led to adequate IOP regulation. For 10 eyes (29%) with persistently elevated IOP, continued topical antiglaucoma therapy was required, while 2 eyes required surgical intervention. The average thickness of the retinal nerve fiber layer and the ganglion cell layer did not change significantly over two years.
conclusionAn increased IOP can occur during the course of anti-VEGF therapy in normotensive eyes. This phenomenon can be conservatively controlled in 94% of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.